Collecting Samples to Find Gene Changes Linked to Pancreatic Cancer Risk in Children
Collects samples from children with pancreatitis to look for gene changes linked to cancer risk.
Plain-language title generated from the registry record
Registry title: Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
Key facts
- Where
- Montreal and Toronto, CanadaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children under 18 with repeated acute pancreatitis or chronic pancreatitis. It collects samples to look for gene changes linked to pancreatic cancer.
- Age
- Under 18 years at enrollment
- Sex
- All sexes can join
- Disease stage
- Acute recurrent pancreatitis (at least 2 episodes of acute pancreatitis with complete pain resolution and at least 1 month pain-free between episodes) or chronic pancreatitis (at least one lasting structural change in the pancreas).
Main reasons for not taking part
- Significant medical illness that, in the investigator's opinion, cannot be controlled with proper therapy or would affect the child's ability to tolerate study procedures
Read by machine on 9 November 2026.
Where in Canada
- The Montreal Children's Hospital of the MUHCMontreal, CanadaTaking people
- Hospital for Sick ChildrenToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT06651580
- Record updated
- 11 September 2026
- Original description
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.Read full original descriptionShow less
Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2)
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.
Inclusion: All subjects/parents must sign an informed consent and/or assent indicating that they are aware of the investigational nature of this study; Subjects/parents must have signed an authorization for the release of their or their child's protected health information; All children must be under 18 years of age at the time of enrollment; All children providing samples should fit the ARP or CP inclusion criteria defined below:; Acute pancreatitis (AP): AP is defined as requiring 2 of the following:; Abdominal pain compatible with AP; Serum amylase and/or lipase values >= 3 times upper limits of normal; Imaging findings of AP, such as gland enlargement, acute inflammatory changes, and fluid collections; ARP is defined as: At least 2 episodes of acute pancreatitis with complete resolution of pain and a >= 1 month pain-free interval between episodes; Chronic Pancreatitis:; Children with at least:; One irreversible structural change in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes; Irreversible structural changes:; Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound [abd US], magnetic resonance imaging/magnetic resonance cholangiopancreatography [MRI/MRCP], computerized tomography [CT], endoscopic retrograde cholangiopancreatography [ERCP], endoscopic US [EUS]); Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >= 2 months) on any imaging; Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP; Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages).
Exclusion: Subjects must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate study interventions.